Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638352 · ClinicalTrials.gov registry record
False/Negative Rate of Lung Percutaneous Needle Biopsy
A clinical trial of Lung Neoplasm, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- 5
- Enrollment target
- 1
- Study location
NCT00638352 is a study of Lung Neoplasm that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 5 participants, below the 555-participant average among 8 other Lung Neoplasm trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00638352, a study of Lung Neoplasm, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
Needle biopsy is a way of determining whether a lung mass is cancerous or benign. Its accuracy was established by research in which patients underwent fine needle aspiration, a kind of needle biopsy that yields samples for cytology (similar to the way a pap smear or a fluid sample would be evaluated for malignant cells). This kind of needle biopsy may supplemented or replaced by core needle biopsy, which yields samples for histology (similar to surgical tissue samples but on a smaller scale) rather than for cytology. Core needle biopsy is believed to be helpful particularly in obtaining a diagnosis in patients who have a lung mass that their doctors think is cancerous but is, in fact, benign. In spite of the advances in needle biopsy, however, there are patients who do receive a pathology report indicating no evidence of cancer but whose lung mass actually is cancerous. The fraction of such patients, among all patients who have no evidence of cancer according to the biopsy, is called the "false negative rate." It is approximately 25% for needle biopsies that consist of fine needle aspiration alone. The false negative rate for needle biopsies that include core biopsy samples is not known. We want to examine the accuracy of needle biopsy in patients who had core samples taken from a lung mass in addition to, or in place of, fine needle aspiration. In this study we will focus on such patients who had no evidence of cancer according to the biopsy, to determine how many actually had a cancer that was missed by the biopsy. To accomplish this goal, we will need to review the medical records of these patients for one of two things: either a definitive diagnosis of the lung mass by some other means (for example, surgical biopsy), or by seeing how the patient does over a period of time (usually in conjunction with medical imaging tests such as chest x-rays or chest CT scans). To establish that a lung mass is benign by observing a patient over time, it is necessary to show th
Conditions Studied
Study Locations (1)
New York
- SUNY Upstate Medical University - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00638352
The ClinicalTrials.gov registry entry for NCT00638352 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 555-participant average among 8 other Lung Neoplasm trials with a reported enrollment target (99% lower). The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Neoplasm appearing as the primary indexed condition, and to 0 interventions.
NCT00638352 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00638352 about?
NCT00638352 is a clinical study titled "False/Negative Rate of Lung Percutaneous Needle Biopsy". Needle biopsy is a way of determining whether a lung mass is cancerous or benign. Its accuracy was established by research in which patients underwent fine needle aspiration, a kind of needle biopsy that yields samples for cytology (similar to the way a pap smear or a fluid sample would be evaluated...
What is the current status of trial NCT00638352?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2010-03. Estimated completion is 2010-04.
What conditions does trial NCT00638352 study?
This clinical trial studies the following conditions: Lung Neoplasm.
Who is sponsoring clinical trial NCT00638352?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00638352 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
RECRUITING · NA
-
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
RECRUITING
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
RECRUITING · Phase 2
-
Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules
ACTIVE NOT RECRUITING · NA
-
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.